Neuromuscular blocking agents (NMB) are frequently used in the Pediatric Intensive Care Unit (PICU), and their use has been correlated with severity of illness measures. While their use may be associated with improvements in measured physiologic variables, these agents are also associated with multiple and potentially fatal adverse effects. A thorough understanding of the physiology and pharmacology of neuromuscular blockade is required for the safe and effective use of these medications.
KeywordsPediatric Intensive Care Unit Neuromuscular Blockade Malignant Hyperthermia Malignant Hyperthermia Neuromuscular Blocking Agent
- Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for post-operative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41:1095–103.PubMedCrossRefGoogle Scholar
- Silverman DG, Donati F. Neuromuscular effects of depolarizing relaxants. In: Silverman DG, editor. Neuromuscular block in perioperative and intensive care. Philadelphia: J.B. Lippincott Company; 1994. p. 239–54.Google Scholar
- Silverman DG, Donati F. Factors affecting pseudocholinesterase and the pharmacokinetics and pharmacodynamics of succinylcholine. In: Silverman DG, editor. Neuromuscular block in perioperative and intensive care. Philadelphia: J.B. Lippicott Company; 1994. p. 255–75.Google Scholar
- Silverman DG, Standaert FG. Anatomy and physiology of neuromuscular transmission. In: Silverman DG, editor. Neuromuscular block in perioperative and intensive care. Philadelphia: J.B. Lippincott Company; 1994. p. 1–10.Google Scholar